Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute

Orphan Therapeutics Accelerator (OTXL) in-licensed OTXL-101, its first pipeline program. The therapy is in development for a severe, rare pediatric metabolic condition; the excerpt provides no clinical results or financial terms.